ArticleMolecules (Basel, Switzerland)2026
Screening and Mechanistic Investigation of Synergistic Xanthine Oxidase Inhibitors Based on Structure-Activity Relationships.
Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
In order to screen the synergistic inhibitors of xanthine oxidase (XOD), the inhibitory activities of 16 flavonoids in Coreopsis tinctoria were evaluated by structure-activity relationship in this study. Eight flavonoids were screened and were observed to have XOD inhibition and antioxidant capacity, and the zero-interaction potential (ZIP) score was used to determine the synergistic effect with allopurinol. Among them, butein and coreopsin showed good synergistic activity (average ZIP > 15). Subsequently, the inhibitory mechanism of butein and coreopsin alone and in combination with allopurinol on XOD was investigated using in vitro experiments. The inhibitory ability of both on XOD was relatively strong. After combination with two chalcones, the enzyme-inhibition effect of allopurinol was significantly improved. Butein and coreopsin can enhance the binding ability of allopurinol to XOD, induce the conformational change of the enzyme, and achieve synergistic inhibition. The binding mode and key amino-acid binding contribution of the complex were analyzed by computer simulation. In summary, the two chalcones might serve as potential XOD inhibitors and synergistic adjuvants for allopurinol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.